The Trastuzumab for Gastric Cancer (ToGA) study established the value of trastuzumab, an anti-HER2-directed monoclonal antibody, for treatment of HER2 + GC and esophago-gastric junction (EGJC). This evidence concerns the gene ERBB2 and gastric cancer.